Get started
Author

Adebayo Ogunniyi

Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology
2015 · Meagan S. Barbee, Adebayo Ogunniyi, et al. · Annals of Pharmacotherapy · 180
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
2015 · Thu Oanh Dang, Adebayo Ogunniyi, et al. · Expert Review of Anticancer Therapy · 153
New Food and Drug Administration–Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia
2018 · Zach R. Click, Amanda N. Seddon, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 18
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency*
2016 · Adebayo Ogunniyi, Mabel Rodriguez, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 14
The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia
2017 · Troy Z. Horvat, Amanda N. Seddon, et al. · Annals of Pharmacotherapy · 6
Risk factors associated with ifosfamide (IFOS)-induced encephalopathy in patients (pts) with metastatic (Met) sarcoma (Sarc).
2017 · Adebayo Ogunniyi, Anjali Varma Desai, et al. · Journal of Clinical Oncology · 1
Efficacy and Risk Factors Analysis of Upfront Autologous Stem Cell Mobilization Using Plerixafor and Granulocyte-Colony Stimulating Factor (GCSF) in Patients with Multiple Myeloma
2014 · Adebayo Ogunniyi, Mabel Rodriguez, et al. · Blood
Works count: 8
Citation count: 372
H-index: 5
I10-index: 4
Year
Topic
Type